Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 11/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380113 | 0.82 | MAP3K5 (0.49) | TTKEPHX1MAP2K4MAPK1MAP3K5 | |
| SCHEMBL5373154 | 0.82 | MAP3K5 (0.49) | TTKEPHX1MAP2K4MAPK1MAP3K5 | |
| SCHEMBL6509704 | 0.79 | MAP2K4 (0.45) | TTKMAP2K4MAPK1AURKAMAP3K5 | |
| SCHEMBL6502512 | 0.79 | MAP2K4 (0.41) | TTKMAP2K4MAPK1AURKAMAP3K5 | |
| SCHEMBL6508775 | 0.78 | PIM1 (0.43) | MAP2K4MAP3K5CLK2CLK3DYRK1A | |
| SCHEMBL6501695 | 0.77 | MAP3K5 (0.40) | TTKMAP2K4MAPK1AURKAMAP3K5 | |
| SCHEMBL5375088 | 0.76 | TTK (0.43) | TTKEPHX1MAP2K4MAPK1MAP3K5 | |
| SCHEMBL4260207 | 0.67 | EPHX1 (0.55) | EPHX1MAPK1 | |
| SCHEMBL12825512 | 0.66 | TTK (0.63) | TTKAURKAAURKB | |
| SCHEMBL1516139 | 0.65 | EPHX1 (1.00) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | TTK 714/4885EPHX1 2793/4885MAP2K4 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.